Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study

INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment option for myelofibrosis (MF). Despite the benefits of long-term relapse-free survival, HSCT can be associated with substantial treatment-related morbidity and mortality. METHODS: This is...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhary, Dharma, Doval, Divya, Khandelwal, Vipin, Setia, Rasika, Handoo, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia-Pacific Blood and Marrow Transplantation Group 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266917/
https://www.ncbi.nlm.nih.gov/pubmed/37324569
http://dx.doi.org/10.31547/bct-2022-003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266917/
https://www.ncbi.nlm.nih.gov/pubmed/37324569
http://dx.doi.org/10.31547/bct-2022-003

Ejemplares similares